Metabolomics-based pancreatic cancer diagnosis marker as well as screening method and application thereof

A technology of diagnostic markers and metabolic markers, applied in scientific instruments, instruments, measuring devices, etc., can solve the problems of high detection sensitivity, huge data volume, and many data characteristics, and achieve high sensitivity and universal applicability

Active Publication Date: 2020-01-03
北京博远精准医疗科技有限公司
View PDF5 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, a bottleneck in the application of metabolomics technology to discover biomarkers lies in its high detection sensitivity, many data features, and a large amount of data. The traditional principal component analysis method will ignore many factors that have a certain impact on the distinction between the two types of samples in order to reduce the number of features. feature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Metabolomics-based pancreatic cancer diagnosis marker as well as screening method and application thereof
  • Metabolomics-based pancreatic cancer diagnosis marker as well as screening method and application thereof
  • Metabolomics-based pancreatic cancer diagnosis marker as well as screening method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Example 1: Screening of pancreatic cancer diagnostic markers

[0063] 1. Research object

[0064] A total of 333 plasma samples from patients with pancreatic cancer and 262 plasma samples from normal healthy controls were included in this study from 4 independent medical centers. The diagnostic criteria for pancreatic cancer were pancreatic ductal adenocarcinoma confirmed by postoperative pathology.

[0065] 2. Plasma non-targeted metabolomics analysis using liquid chromatography-mass spectrometry

[0066] All plasma samples were centrifuged and stored in a -80°C refrigerator. Plasma samples were taken out during the research, and after sample pretreatment, metabolomics analysis was performed using high-performance liquid chromatography-mass spectrometry to obtain the original metabolic fingerprint of the sample including chromatographic and mass spectrometric information. The specific operation is as follows:

[0067] 2.1 Instruments and reagents

[0068] Experime...

Embodiment 2

[0097] Example 2: Construction of a pancreatic cancer diagnostic model using 19 plasma metabolic markers

[0098] 1. Research object

[0099] This study included 333 plasma samples from pancreatic cancer patients and 262 healthy controls with normal physical examination from 4 independent medical centers, which were from the same source as the characteristic screening samples (595 cases). Among them, 495 cases of pancreatic cancer patients and healthy controls were used for the training set, and 100 cases were used for the test set. Among them, the diagnostic criteria of pancreatic cancer are single or multiple pancreatic cancers with a diameter of less than 3 cm confirmed by imaging examination and tissue biopsy.

[0100] 2. Plasma Targeted Metabolomics Analysis Using Liquid Chromatography-Mass Spectrometry

[0101] All plasma samples were centrifuged and stored in a -80°C refrigerator. Plasma samples were taken out during the research, and after sample pretreatment, targe...

Embodiment 3

[0128] Example 3: Construction of a pancreatic cancer diagnostic model using 17 plasma metabolic markers

[0129] The research objects and detection and analysis methods of this embodiment are the same as those of Example 2, except that 17 plasma metabolic markers (including lysophosphatidylcholine LPC 14:0, lysophosphatidylcholine 14:0, lysophosphatidylcholine Alkaline LPC 16:0, Lysophosphatidylcholine LPC 18:1, Lysophosphatidylcholine LPC 20:4, Phosphatidylcholine PC 16:0-16:0, Phosphatidylcholine PC 16:0-18: 1. Phosphatidylcholine PC 18:0-18:2, Phosphatidylcholine PC 18:0-20:3, Phosphatidylcholine PC16:0-22:5, Phosphatidylcholine PC 18:0-22 :5, Phosphatidylcholine PC O-16:0-18:2, Lysophosphatidylethanolamine LPE22:4, Phosphatidylethanolamine PE 16:0-18:2, Sphingomyelin SM d18:1 / 18:0, Sphingomyelin Phospholipids SM d18:2 / 24:1, sphingomyelin SM d18:2 / 24:2, diglycerides DG 18:1-18:1) for machine learning and modeling, the sensitivity of the obtained model (sensitivity), spec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a metabolomics-based pancreatic cancer diagnosis marker and a screening method thereof. The diagnosis marker comprises any one or a combination of more of 31 plasma metabolic markers. The invention also provides a method for constructing a diagnosis model by using the pancreatic cancer diagnosis marker and an application in a diagnosis kit. According to the method, non-target metabolomics analysis is carried out on the plasma of a patient through a high-efficiency liquid chromatography mass spectrometry technology, the difference metabolite between the pancreatic cancerpatient and the normal people is found through an artificial intelligence data analysis technology, and the diagnosis capability of the specific differential metabolite, namely the pancreatic cancerdiagnosis marker in the diagnosis of the pancreatic cancer is further verified through target metabolomics analysis and machine learning modeling.

Description

technical field [0001] The invention belongs to the field of clinical examination and diagnosis, and specifically relates to a diagnostic marker for pancreatic cancer based on metabolomics and machine learning analysis technology, a screening method for the diagnostic marker, a method for constructing a diagnostic model using the diagnostic marker, and the diagnostic method. Application of markers in the diagnosis of pancreatic cancer. Background technique [0002] Pancreatic cancer (pancreatic cancer) is a malignant disease of the digestive tract with a high degree of malignancy and is difficult to diagnose and treat. Its incidence has been rising rapidly in recent years. According to the national cancer statistics released by the National Cancer Center of China in January 2019, pancreatic cancer ranks tenth in the incidence of malignant tumors in my country, and ranks seventh in the mortality rate. The current status of diagnosis and treatment is not optimistic. Long-term...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/86
CPCG01N30/8686
Inventor 尹玉新王光熙庞瑞芳
Owner 北京博远精准医疗科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap